The difference between reacting and preventing
Millions of Brazilians living with diabetes carry not only the physical weight of a chronic illness but a quieter burden of anxiety, isolation, and uncertainty that current care systems have largely failed to address. A global study has surfaced what many patients already know: that the gap between what medicine can offer and what the public system provides is not merely technical, but deeply human. Continuous glucose monitoring technology — already standard in wealthier nations — remains a privilege of income in Brazil, even as patients and clinicians alike describe it as a turning point in how the disease can be lived with. The question now before the country is whether equity in health will be treated as a legislative formality or a genuine commitment.
- Seven in ten Brazilian diabetics report significant emotional distress, with nearly four in five gripped by anxiety about their future — a psychological toll that rivals the physical one.
- Over half face daily mobility constraints and disrupted sleep from nocturnal glucose swings, turning ordinary life into a series of unpredictable crises.
- Patients are not asking for the impossible: 44–53% specifically advocate for AI-powered continuous glucose monitors already standard in France, the UK, and the US.
- Brazil's Health Ministry rejected public system coverage of the technology in January 2025, even as Congress passed a bill mandating free provision — leaving the outcome suspended in legislative limbo.
- The stakes are systemic as well as personal: wider CGM adoption would reduce hospitalizations and emergency costs, yet the devices remain accessible only to those who can pay privately.
A study conducted last September by the Global Wellness Institute and Roche Diagnostics, surveying over four thousand people across twenty-two countries including roughly eight hundred Brazilians, reveals the profound emotional and practical toll of diabetes in the country. Nearly four in five Brazilian patients report anxiety about the future, two in five feel isolated by their condition, and more than half say the disease limits their ability to leave home or sleep through the night undisturbed.
Brazil ranks sixth globally in diabetes cases, with 16.6 million adults diagnosed — yet only thirty-five percent of patients feel confident managing their own condition. The technology patients say could change that equation is continuous glucose monitoring: sensors that track blood sugar in real time and, crucially, predict where it is heading. Fifty-three percent of those surveyed named predictive capability as the feature they most want, a figure that rises to sixty-eight percent among people with type 1 diabetes, for whom swings are most dangerous.
André Vianna of the Brazilian Diabetes Society explains that these sensors don't just improve individual outcomes — they reduce hospitalizations and emergency room visits, easing pressure on the public health system. France, the United Kingdom, and the United States already provide or widely cover the devices. In Brazil, four companies sell them, but only to those who can afford to pay out of pocket.
In January 2025, Brazil's Health Ministry formally declined to incorporate continuous glucose monitoring into the public health system. The decision came just weeks after Congress approved a bill that would require exactly that — free provision for all public system patients. That bill still awaits approval from two congressional committees and a full vote in both chambers. The Health Ministry declined to comment. For now, a technology that patients need and doctors endorse remains a privilege of wealth, its promise visible but unreachable for most Brazilians living with diabetes.
Seven out of every ten Brazilians living with diabetes say the disease weighs heavily on their emotional wellbeing. That finding comes from a study conducted last September by the Global Wellness Institute in partnership with Roche Diagnostics, which surveyed more than four thousand people across twenty-two countries—roughly eight hundred of them in Brazil. The numbers paint a picture of a population struggling not just with a chronic illness, but with the psychological burden that comes with it. Nearly four in five report anxiety about what the future holds. Two in five feel isolated because of their condition. For fifty-six percent, diabetes has become a practical barrier to leaving home for the day. Another forty-six percent find themselves constrained by ordinary situations—sitting in traffic, attending long meetings—that most people navigate without thought. Fifty-five percent wake up without feeling truly rested, their sleep fractured by the blood sugar swings that happen while they sleep.
Brazil ranks sixth globally in diabetes cases, with sixteen point six million adults diagnosed according to the International Diabetes Federation's 2025 atlas. Yet despite the scale of the problem, most patients say they do not feel adequately supported by the current system of care. Only thirty-five percent feel truly confident managing their own condition. This gap between need and confidence points to something deeper than simple lack of treatment—it suggests a system that leaves people uncertain, reactive, always bracing for the next crisis.
What patients are asking for is technology that could shift that dynamic. Forty-four percent of those surveyed advocate for smarter devices capable of predicting changes in glucose levels before they happen. Among those currently using traditional finger-stick tests or basic glucose meters, forty-six percent say continuous glucose monitoring sensors—devices that track blood sugar in real time—should become standard because they can alert users to problems before they arrive. Fifty-three percent identify predictive capability as the single most valuable feature they want: the ability to know what their glucose will do in the hours ahead. That number climbs to sixty-eight percent among people with type 1 diabetes, for whom blood sugar swings are more dramatic and dangerous. Knowing those trends in advance would give fifty-six percent of Brazilian patients a sense of control over their disease. For forty-eight percent, it would simply mean fewer surprises, fewer sudden crashes and spikes that disrupt work, sleep, and daily life.
André Vianna, vice president of the Brazilian Diabetes Society, frames the case for these sensors in clinical terms. Early diagnosis and continuous medical monitoring are essential to prevent complications, he notes. But for type 1 patients especially, whose glucose levels fluctuate unpredictably, continuous monitoring through sensors represents a genuine shift in what's possible. A person wearing such a sensor can see what their glucose will be in thirty minutes and take preventive action before a crisis develops. The benefits extend beyond the individual: patients using these devices end up in hospitals less often, in emergency rooms less often, which reduces costs for the public health system while improving outcomes. In wealthy countries, this is already standard practice. France and the United Kingdom provide the devices free through their national health systems. The United States makes them widely available through private insurers. But in Brazil, they remain concentrated among people with money to buy them privately. Four companies sell the devices in the country, but the public health system has never rolled them out at scale.
That gap became official policy in January 2025, when Brazil's Health Ministry announced it would not incorporate continuous glucose monitoring into the Sistema Único de Saúde—the country's public health system. The decision came despite a bill approved by Congress in December that would require exactly that: free provision of glucose monitoring devices to all diabetes patients in the public system. That bill still needs final approval from two more congressional committees and then passage by both chambers before it becomes law. The Health Ministry, when contacted, declined to comment on the decision or the pending legislation. For now, the technology that patients say they need, that doctors say would improve their lives and reduce system costs, remains out of reach for most Brazilians with diabetes—available only to those who can afford it, withheld from those who cannot.
Citações Notáveis
The ideal for these patients is continuous glucose monitoring through sensors already widely available in much of the world. A person can understand early what will happen in the next hours, knowing whether their glucose will be high or low and taking preventive action.— André Vianna, vice president of the Brazilian Diabetes Society
These devices reduce hospitalizations and emergency room visits, which improves health and decreases treatment costs. That's why continuous monitoring is already well-established globally.— André Vianna, vice president of the Brazilian Diabetes Society
A Conversa do Hearth Outra perspectiva sobre a história
Why does this matter so much to people? It's just a different way of measuring blood sugar, isn't it?
It's not really about measurement—it's about time. A finger-stick test tells you what your glucose is right now. A continuous sensor tells you what it will be in thirty minutes. That difference is the difference between reacting and preventing. For someone with type 1 diabetes, that's the difference between a normal day and a medical emergency.
And the emotional piece—why does that loom so large in the research?
Because diabetes isn't just a physical condition. It's uncertainty living in your body. You don't know when your blood sugar will crash. You can't plan a day out without anxiety. You wake up exhausted because your body was fighting glucose swings all night. A sensor that predicts what's coming doesn't cure that, but it transforms it from chaos into something you can anticipate and manage.
So why hasn't Brazil's public system adopted this? It sounds like it would save money.
That's the paradox. The evidence shows it does save money—fewer hospitalizations, fewer emergency visits. But the upfront cost is significant, and the decision-makers chose not to absorb it. Meanwhile, Congress is pushing back with legislation. It's a standoff between what the data says should happen and what the bureaucracy has decided.
Who loses in that standoff?
The sixteen point six million Brazilians with diabetes who don't have the money to buy a sensor privately. They keep managing the old way—testing, guessing, living with the uncertainty and the exhaustion. The wealthy get the technology. Everyone else waits.
Is there any sense this will change?
The bill is still moving through Congress. But these things move slowly, and the Health Ministry has already drawn a line. It could go either way.